JP7046973B2 - 抗ｏｘ４０抗体およびその使用 - Google Patents

抗ｏｘ４０抗体およびその使用 Download PDF

Info

Publication number
JP7046973B2
JP7046973B2 JP2019551983A JP2019551983A JP7046973B2 JP 7046973 B2 JP7046973 B2 JP 7046973B2 JP 2019551983 A JP2019551983 A JP 2019551983A JP 2019551983 A JP2019551983 A JP 2019551983A JP 7046973 B2 JP7046973 B2 JP 7046973B2
Authority
JP
Japan
Prior art keywords
antibody
cells
antigen
adi
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019551983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515247A5 (enExample
JP2020515247A (ja
Inventor
ツン、アンディー
ヘマンタ、バルアー
リウ、シャオリン
チェン、チェン
リウ、ジュンジャン
チェン、ビンリャン
ファン、ウェイフェン
Original Assignee
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド filed Critical イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド
Publication of JP2020515247A publication Critical patent/JP2020515247A/ja
Publication of JP2020515247A5 publication Critical patent/JP2020515247A5/ja
Application granted granted Critical
Publication of JP7046973B2 publication Critical patent/JP7046973B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019551983A 2017-03-25 2018-03-23 抗ｏｘ４０抗体およびその使用 Expired - Fee Related JP7046973B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710185400.8 2017-03-25
CN201710185400.8A CN108623686A (zh) 2017-03-25 2017-03-25 抗ox40抗体及其用途
PCT/CN2018/080315 WO2018177220A1 (zh) 2017-03-25 2018-03-23 抗ox40抗体及其用途

Publications (3)

Publication Number Publication Date
JP2020515247A JP2020515247A (ja) 2020-05-28
JP2020515247A5 JP2020515247A5 (enExample) 2021-08-19
JP7046973B2 true JP7046973B2 (ja) 2022-04-04

Family

ID=63674253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019551983A Expired - Fee Related JP7046973B2 (ja) 2017-03-25 2018-03-23 抗ｏｘ４０抗体およびその使用

Country Status (6)

Country Link
US (1) US11498972B2 (enExample)
EP (1) EP3604338A4 (enExample)
JP (1) JP7046973B2 (enExample)
CN (2) CN108623686A (enExample)
CA (1) CA3056972A1 (enExample)
WO (1) WO2018177220A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145993B2 (en) 2016-06-08 2024-11-19 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
EP3889180A4 (en) * 2018-11-26 2023-01-04 Nanjing GenScript Biotech Co., Ltd. ANTI-OX40 HUMANIZED MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE
MX2021007589A (es) * 2018-12-21 2021-12-10 23Andme Inc Anticuerpos anti il-36 y procedimientos de uso de estos.
CN111363040B (zh) * 2018-12-25 2023-07-14 杭州翰思生物医药有限公司 抗ox40的单克隆抗体及其应用
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
CN110003338B (zh) * 2019-04-16 2021-04-23 北京免疫方舟医药科技有限公司 抗ox40抗体及其应用
CN110004177A (zh) * 2019-04-22 2019-07-12 中国食品药品检定研究院 一种检测抗ox40抗体的方法及其应用
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
JP7702954B2 (ja) * 2019-12-27 2025-07-04 ハイファイバイオ， インコーポレイテッド 抗ｏｘ４０抗体およびその使用
CN113429483A (zh) * 2020-03-23 2021-09-24 百奥泰生物制药股份有限公司 一种免疫细胞激活剂的开发及应用
CN114014906B (zh) * 2020-06-24 2024-01-12 夏尔巴生物技术(苏州)有限公司 一种利用阳离子交换层析纯化疏水性蛋白的方法
CN111704671B (zh) * 2020-08-19 2020-11-24 广东赛尔生物科技有限公司 Ox40抗体及其在治疗癌症中的应用
WO2023060244A1 (en) * 2021-10-07 2023-04-13 Lankenau Institute For Medical Research Methods and compositions including novel antibodies for diagnosing covid-19 variants
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
CN114478789B (zh) * 2021-12-20 2024-06-14 安徽安科生物工程（集团）股份有限公司 抗pd-l1与ox40双特异性抗体及其用途
CN114966061B (zh) * 2022-07-28 2022-10-21 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法
WO2024141049A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗ox40抗体及其应用
CN117164720A (zh) * 2023-04-28 2023-12-05 苏州大学 Gitr-ox40双特异性单链抗体的制备方法
EP4755917A1 (en) * 2023-08-04 2026-06-10 Fortvita Biologics Inc. Anti-ox40l antibody and use thereof
CN121930348B (zh) * 2026-03-27 2026-06-09 南京优迈瑞保生物科技有限公司 一种抗人ox40的抑制性抗体或其抗原结合片段、制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2010105256A1 (en) 2009-03-13 2010-09-16 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
JP2013538057A (ja) 2010-08-23 2013-10-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK1060247T3 (da) 1998-02-24 2009-01-26 Sisters Of Providence In Orego Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006121167A1 (ja) 2005-05-12 2006-11-16 Nsk Ltd. 直動案内装置
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP2593567B1 (en) 2010-07-15 2016-04-20 The Regents of The University of California Biomarkers for diagnosis of stroke and its causes
RS57840B1 (sr) * 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
SG11201607969XA (en) 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
CN106999583A (zh) * 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
AU2016271111B2 (en) * 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
EP3303397A1 (en) * 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
AU2016274585A1 (en) * 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
AU2018256453B2 (en) 2017-04-20 2024-02-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2010105256A1 (en) 2009-03-13 2010-09-16 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
JP2013538057A (ja) 2010-08-23 2013-10-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法

Also Published As

Publication number Publication date
CN108623686A (zh) 2018-10-09
US11498972B2 (en) 2022-11-15
US20200140562A1 (en) 2020-05-07
EP3604338A1 (en) 2020-02-05
JP2020515247A (ja) 2020-05-28
CA3056972A1 (en) 2018-10-04
EP3604338A4 (en) 2021-04-28
CN110536903A (zh) 2019-12-03
WO2018177220A1 (zh) 2018-10-04
CN110536903B (zh) 2022-12-16

Similar Documents

Publication Publication Date Title
CN110536903B (zh) 抗ox40抗体及其用途
JP7855519B2 (ja) がんを処置するための抗ｃｃｒ８抗体
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
JP7545437B2 (ja) Ｈｅｒ３抗原結合性分子
CN112513080B (zh) Vista抗原结合分子
TWI640536B (zh) 抗體
JP6840127B2 (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
CN108623685B (zh) 抗ox40抗体及其用途
BR112020007725A2 (pt) anticorpo anti-pd-l1 e usos do mesmo
CN110392694A (zh) 针对pd-1的抗体及其用途
CN114907481A (zh) Icos的抗体
KR20250134734A (ko) Cub 도메인-함유 단백질 1(cdcp1)에 대한 항체 및 이의 용도
CN120757647B (zh) Tigit抗体及其用途
HK40017894A (en) Anti-ox40 antibody and use thereof
HK40075856A (en) Her3 antigen-binding molecules
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40017894B (en) Anti-ox40 antibody and use thereof
HK40052624A (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK1248127B (en) Antibodies to icos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210604

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220323

R150 Certificate of patent or registration of utility model

Ref document number: 7046973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees